Loading clinical trials...
Loading clinical trials...
Triglyceride Glucol Index for Predicting the Value of No-Reflow in Patients Undergoing Emergency PCI for Acute Myocardial Infarction
The goal of this prospective cohort study is to investigate the relationship between the TyG index and early identification of MVO in AMI patients undergoing emergency PCI and CMR imaging. The study will enroll approximately 300 AMI patients treated at Xiangya Third Hospital of Central South University from June 2024 to August 2025. The main questions it aims to answer are: * How does the TyG index correlate with the early detection of MVO? * What differences in cardiovascular adverse events during hospitalization exist between groups with varying TyG index levels? Participants will undergo emergency PCI and CMR imaging within 3-7 days post-procedure. Data collected will include demographic characteristics, clinical history, coronary angiography data, laboratory test indicators (especially metabolic markers such as blood glucose and lipids), IVUS-related plaque information, and CMR results.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Xiangya Third Hospital of Central South University
Changsha, Hunan Province,China, China
Start Date
June 1, 2024
Primary Completion Date
August 31, 2025
Completion Date
August 31, 2025
Last Updated
July 2, 2025
300
ESTIMATED participants
Lead Sponsor
The Third Xiangya Hospital of Central South University
NCT06744322
NCT06118281
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06745141